Free Melissa, Choi Hena, Baweja Ritika
Drs. Free and Baweja are with Department of Psychiatry and Behavioral Health, Penn State Health Milton S. Hershey Medical Center in Hershey, Pennsylvania.
Ms. Choi is with Penn State College of Medicine in Hershey, Pennsylvania.
Innov Clin Neurosci. 2024 Jun 1;21(4-6):11-13. eCollection 2024 Apr-Jun.
Stimulants are the first-line pharmacological treatment for attention deficit hyperactivity disorder (ADHD). We present the unique case of a patient who developed a chewing compulsion when taking mixed amphetamine salts (MAS). A 32-year-old female patient with a past medical history of gastroesophageal reflux disease (GERD), gastroparesis, and migraines was seen for initial psychiatric assessment due to concerns for irritability. She was diagnosed with post-traumatic stress disorder (PTSD); generalized anxiety disorder; ADHD, inattentive type; and unspecified bipolar disorder. Lamotrigine was started and titrated to 25mg twice per day, with improved mood stability. MAS immediate-release (IR) was started at 2.5mg and titrated to 5mg daily for ADHD. She then experienced an uncontrollable urge to chew, finding relief when chewing on a child's teething necklace, which provided satisfaction and a reduction in anxiety. She denied jaw tightness or teeth grinding. The dose of MAS IR was reduced to 2.5mg daily with improvement in symptoms and later increased again to 5mg daily, which she was then able to tolerate. Stereotyped biting behaviors have been observed in rats with the use of amphetamines, and the onset of compulsive behavior has emerged in children with the use of dextroamphetamine. However, this is the first known case of compulsive chewing or biting movements reported in humans with MAS use. This case highlights the need to assess patients for adverse events, such as compulsive biting and chewing movements or other oral facial stereotypies, after commencement of stimulants, including MAS.
兴奋剂是治疗注意力缺陷多动障碍(ADHD)的一线药物治疗方法。我们报告了一例独特的病例,一名患者在服用混合苯丙胺盐(MAS)时出现了咀嚼强迫行为。一名32岁女性患者,既往有胃食管反流病(GERD)、胃轻瘫和偏头痛病史,因易怒问题前来进行初次精神科评估。她被诊断为创伤后应激障碍(PTSD)、广泛性焦虑障碍、注意力不集中型ADHD和未特定的双相情感障碍。开始使用拉莫三嗪并滴定至每日两次,每次25mg,情绪稳定性有所改善。开始使用MAS速释片(IR),起始剂量为2.5mg,滴定至每日5mg用于治疗ADHD。随后,她经历了无法控制的咀嚼冲动,在咀嚼儿童出牙项链时能得到缓解,这能带来满足感并减轻焦虑。她否认有牙关紧闭或磨牙现象。MAS IR的剂量减至每日2.5mg后症状有所改善,后来又增至每日5mg,此时她能够耐受。在使用苯丙胺的大鼠中观察到了刻板的咬啮行为,在使用右旋苯丙胺的儿童中出现了强迫行为发作。然而,这是已知首例在使用MAS的人类中报告的强迫性咀嚼或咬啮动作病例。该病例强调了在开始使用包括MAS在内的兴奋剂后,需要评估患者是否出现不良事件,如强迫性咬啮和咀嚼动作或其他口面部刻板行为。